Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 4/20 | 0.37 |
| ▸ | NQO1 | P15559 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369288 | 1.00 | IDO1 (0.37) | IDO1NQO2NQO1MEN1USP2 | |
| Hydrochloric Acid SCHEMBL1650422 | 0.98 | NQO2 (0.36) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL8543978 | 0.94 | IDO1 (0.35) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL5082535 | 0.92 | IDO1 (0.37) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL8542166 | 0.92 | MEN1 (0.44) | NQO2NQO1MEN1USP2LMNA | |
| SCHEMBL8546191 | 0.91 | IDO1 (0.37) | IDO1NQO2NQO1 | |
| SCHEMBL8545959 | 0.90 | NQO2 (0.38) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL8543922 | 0.89 | MEN1 (0.37) | NQO2NQO1MEN1USP2LMNA | |
| SCHEMBL8543902 | 0.87 | IDO1 (0.35) | IDO1NQO2NQO1 | |
| SCHEMBL8547450 | 0.86 | NQO1 (0.43) | NQO2NQO1PAX8SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| EP-2603222-B1 | COMBINATORY CANCER TREATMENT | UNIV MONTREAL (CA) | 2018-10-17 | — | — | EP | claimed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12583871-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2001062251-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-0487097-B1 | Pyrazoloacridone derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5220026-A | Antitumor agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0487097-A1 | Pyrazoloacridone derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | IDO1 3048/4885NQO2 1072/4885NQO1 68/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | IDO1 3257/4885NQO2 744/4885NQO1 1627/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | IDO1 777/4885NQO2 539/4885NQO1 236/4885 |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | MGMT, NNMT, GNMT | IDO1 3918/4885NQO2 867/4885NQO1 117/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | IDO1 777/4885NQO2 539/4885NQO1 236/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | IDO1 3216/4885NQO2 2192/4885NQO1 3173/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | IDO1 3619/4885NQO2 191/4885NQO1 348/4885 |
| US-12583871-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | IDO1 3383/4885NQO2 596/4885NQO1 1431/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | IDO1 3073/4885NQO2 1852/4885NQO1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.